Transgene
Most popular related searches
cancer cell
iv infusion
cancer cell destruction
immune response
gastrointestinal
solid tumor
clinical trial
chemotherapy
intestine stomach
pancreas colon
Attacking the tumor on several fronts
TG6002 combines several mechanisms of action to:
- directly and selectively destroy the cancer cells (oncolysis) by causing immunogenic cell death;
- induce an immune response, following the release of antigens during the oncolysis;
- allow the production of chemotherapy (5-FU), directly in the tumor.
First promising results
Transgene is developing TG6002 for the treatment of several solid tumors, such as gastro-intestinal adenocarcinoma (stomach, pancreas and colon). Phase I interim results demonstrate that after IV infusion, TG6002 was detected in the tumor and induced the production of 5-FU. No major SAE have been observed.
Sale of the rights in China
Tasly Biopharmaceutical Group Co, Ltd. acquired research, development and commercialization rights of the technology of TG6002 (T601) for Greater China in 2018.
